Curium Pharma (India) Profile
Key Indicators
- Authorised Capital ₹ 10.30 Cr
as on 17-11-2024
- Paid Up Capital ₹ 10.30 Cr
as on 17-11-2024
- Company Age 20 Year, 2 Days
- Last Filing with ROC 31 Mar 2024
- Revenue 23.52%
(FY 2023)
- Profit 54.63%
(FY 2023)
- Ebitda 51.05%
(FY 2023)
- Net Worth 22.81%
(FY 2023)
- Total Assets 15.54%
(FY 2023)
About Curium Pharma (India)
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 10.30 Cr and a paid-up capital of Rs 10.30 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Curium Pharma (India) Private Limited India is Shikha Singhal as COMPANY SECRETARY. Krishna Tatineni, Xavier Defourt, and Susamoy Mishra serve as directors at the Company.
- CIN/LLPIN
U24230MH2004PTC150212
- Company No.
150212
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Dec 2004
- Date of AGM
20 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Curium Pharma (India)?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shikha Singhal  | Company Secretary | 22-Jun-2019 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Krishna Tatineni  | Director | 17-Feb-2018 | Current |
Xavier Defourt  | Director | 11-Nov-2020 | Current |
| Susamoy Mishra | Director | 07-Mar-2024 | Current |
Financial Performance of Curium Pharma (India).
Iba Molecular Imaging (India) Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 23.52% increase. The company also saw a substantial improvement in profitability, with a 54.63% increase in profit. The company's net worth Soared by an impressive increase of 22.81%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Curium Pharma (India)?
In 2022, Curium Pharma (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Curium Pharma (India)?
Curium Pharma (India) has a workforce of 26 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Curium Pharma (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Curium Pharma (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
